乐天堂fun88

President Yang Yifeng of Pingshan District Central Hospital Visits Shenzhen Cell Valley for Academic Exchange

Date:02-21  Hits:  Belong to:News & Events

图片.png

On February 19, a delegation led by Yang Yifeng, President of Pingshan District Central Hospital, visited Shenzhen Cell Valley for an academic exchange. The delegation included Xia Liangwei, Vice President; Professor Chen Jinwei, Director of the Department of Rheumatology and Immunology; Professor Sun Junzhong, Director of the Department of Oncology; and Tan Zhiping, Director of the Central Laboratory. They were warmly received by Shi Yuanyuan, Chairman and Professor; Wang Jianxun, Chief Scientist and Professor; Fu Yuchen, Assistant to the Chairman; Sun Rui, Minister of the Marketing Department; and Wang Lu, Director of the General Office.

图片.png

图片.png

Accompanied by Professor Shi Yuanyuan, the guests toured the Smart Exhibition Hall of Shenzhen Cell Valley, gaining a deeper understanding of the company's strategic deployment, the uniqueness of its core technologies, and future development trends. They also visited the production workshops and R&D laboratories, gaining an intuitive sense of the operational workflows and the production and quality management systems.

图片.png

During the symposium, Chairman Shi Yuanyuan first extended a warm welcome to the guests and detailed the company's advantages in cell preparation quality control along with several successful treatment cases. Shenzhen Cell Valley ensures the safety and efficacy of cell therapy products through its advanced preparation processes, strict quality control procedures, and extensive clinical experience. Subsequently, Professor Shi Yuanyuan analyzed the current national policy support and expected prospects for the cell therapy field based on overall industry development trends. He also shared Shenzhen Cell Valley's successful experiences in Investigator-Initiated Trials (IIT), emphasizing the company's strengths in technology translation and clinical application.

President Yang Yifeng introduced the development history and current status of Pingshan District Central Hospital, particularly the significant achievements made in discipline construction, talent development, and medical services since its opening in 2023. President Yang stated that as a Grade III-A comprehensive research-oriented hospital, the hospital is committed to providing patients with the most advanced medical technologies. By introducing discipline leaders from Xiangya School of Medicine and cooperating closely with The Second Xiangya Hospital, the hospital is implementing the "Three Transfers" of high-end medical brands, technologies, and personnel to strengthen regional medical services. He noted that this visit aims to leverage the technological advantages of Shenzhen Cell Valley and geographical proximity to jointly promote the clinical application of cell therapy.

During the discussion, both parties engaged in in-depth deliberations on the development and application of universal cell therapy products. Shenzhen Cell Valley will provide full-process technical support to Pingshan District Central Hospital based on its technical accumulation and innovation capabilities, assisting the hospital's development in the field of cell therapy. Both parties reached a consensus on further deepening cooperation to advance clinical applications.

This exchange has laid a solid foundation for collaboration between Shenzhen Cell Valley and Pingshan District Central Hospital. In the future, both parties will work together to explore more possibilities in clinical applications, providing patients with more efficient and safer treatment solutions and promoting the widespread use of cell therapy for major diseases.

 

About Pingshan District Central Hospital

图片.png

Pingshan District Central Hospital is a modern public medical institution constructed according to Grade III-A general hospital standards, officially opening in December 2023. The first phase plans for 800 beds and has opened 31 clinical and medical technology departments, with an annual outpatient and emergency volume of nearly 50,000. The hospital cooperates deeply with The Second Xiangya Hospital of Central South University, introducing high-quality medical resources to fill multiple regional medical gaps. The hospital has appointed Yang Yifeng, a national-level medical management talent from Xiangya School of Medicine, as its president and introduced a group of domestic renowned experts as discipline leaders and operational management talents. This lays a solid foundation for high-level discipline construction and medical services, aiming to build a medical highland in eastern Shenzhen, provide high-quality services for regional residents, and assist in the construction of "Healthy Pingshan".


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@wfzydp.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software